RBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) with a price target of $543. Yesterday an FDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Hot Comments

AdCom Approval, Reservations on Praluent Largely Inline with Expectations; Roth Affirms Regeneron (REGN) at 'Neutral'June 10, 2015 7:54 AM Regeneron (REGN) PRALUEN Panel Commentary Could Result in Narrower-Than-Expected Labeling, BMO Capital SaysJune 10, 2015 7:48 AM FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent(r) (alirocumab) Injection for Patients with HypercholesterolemiaJune 9, 2015 6:48 PM Regeneron (REGN) Confirms FDA Panel Backing of PraluentJune 9, 2015 6:34 PM Esperion (ESPR), Amgen (AMGN) Shares Weaken Post-Market After Praluent Gets FDA BackingJune 9, 2015 5:39 PM Regeneron (REGN) and Sanofi's (SNY) Praluent Wins FDA Panel Backing - BloombergJune 9, 2015 4:52 PM Sanofi (SNY) 'Seemingly Committed' to MannKind's (MNKD) Afrezza, RBC Says; 2nd-Half Efforts to Focus on AwarenessJune 9, 2015 12:04 PM